Atavistik Bio’s JAK2 V617F mutant-selective inhibitors have the potential to address the significant unmet needs of patients with myeloproliferative neoplasms by providing disease-modifying efficacy ...
Treatment with programmed cell death 1/programmed cell death ligand 1 inhibitors for Kaposi sarcoma: A systematic review and meta-analysis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
Myeloproliferative neoplasms (MPNs) represent a cluster of conditions characterized by the excessive production of blood cells within the bone marrow. Among MPN patients, abnormal quantities of red ...
The Janus kinase 2 (JAK2) protein mediates signaling from several cytokine receptors in the regulation of hematopoiesis and immune responses. Somatic mutations in human JAK2 lead to constitutive ...
ZRSR2 mutations are linked to JAK2 V617R-driven MPNs but are insufficient alone for disease progression. CRISPR-Cas9 studies showed ZRSR2 loss causes intron retention and transcriptional changes ...
Please provide your email address to receive an email when new articles are posted on . Patients with myelofibrosis who cleared their mutations 30 days following stem cell transplantation experienced ...
Concurrent ET and WM in a patient highlights challenges in managing coexisting myeloproliferative and lymphoplasmacytic malignancies. Distinct genetic mutations in the patient suggest independent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback